Longboard Pharmaceuticals to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
Longboard Pharmaceuticals (Nasdaq: LBPH) announced that Brandi Roberts, CFO, will participate in the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 12:35 PM ET. She will be a panelist in the session titled "Got My Mind Set On You - Advancing Novel Epilepsy Targets". Interested attendees can access the presentation via the Investors Relations section on Longboard’s website, with the presentation archived for 30 days post-event.
Longboard is focused on innovative therapies for neurological diseases, advancing products targeting specific GPCRs.
- None.
- None.
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present as a panelist at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 12:35PM ET.
Presentation Details:
Panel Title: Got My Mind Set On You - Advancing Novel Epilepsy Targets
Date/Time: Wednesday, August 10, at 12:35PM ET in Track 1
To access a webcast of the presentation, please visit the “Events & Presentations” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/. The presentation will be archived on the website for at least 30 days following the event.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s participation in the upcoming conference, Longboard’s clinical and preclinical programs, ability to develop and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
FAQ
When will Longboard Pharmaceuticals present at the Wedbush PacGrow Healthcare Virtual Conference?
Who is presenting for Longboard Pharmaceuticals at the conference?
What is the title of the panel discussion involving Longboard Pharmaceuticals?
How can I access the webcast of Longboard Pharmaceuticals' presentation?
How long will the presentation by Longboard Pharmaceuticals be available online?
